- Global Pharma News & Resources

Fumiaki Ikeno, Medtech and Data Expert, Joins Omniscience as an Advisor

PALO ALTO, Calif.--(BUSINESS WIRE)--#AI--Omniscience today announced that Fumiaki Ikeno, Program Director (U.S.) Japan Biodesign, Stanford Biodesign, Cardiovascular Medicine, Stanford University, has joined the company as an advisor. In this role, Dr. Ikeno, an expert in a wide variety of medical devices, will help the company define and tailor its computational insurance and other health-related artificial intelligence applications.

“Omniscience has some of the most advanced artificial intelligence available to the insurance industry and other parts of the health technology realm,” said Dr. Ikeno. “I am pleased to contribute to the unique insights the company’s technology can bring to customers.”

Dr. Ikeno is a researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre-clinical studies including GLP for medical devices and regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing," whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program, which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (U.S.) for Japan Biodesign. Dr. Ikeno is co-founder and board member of U.S.-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

Dr. Ikeno has insights into the impact of the aging population and its implications for long-term health and medical devices that can be used to treat them. Omniscience will be able to learn from this perspective and refine its computational insurance products as appropriate. Moreover, since the core Omniscience technology platform has applications in many industries beyond insurance, Dr. Ikeno will be able to contribute to the vision for future products, including extending Omniscience products to the medical device simulation and testing realm.

“We are honored that Dr. Ikeno has agreed to be a part of the Omniscience family,” said Sunil Rawat, Omniscience co-founder and CEO. “He brings an insight into the importance of data in the future of medical technology and will help our company see how we can make our greatest contribution to the industry.”

About Omniscience

Omniscience ( is the first company to enable the Computational Insurance™ business. Because of unique breakthrough distributed technology that can process many layers of business and data complexity completely and rapidly, Omniscience customers can approach their businesses in entirely new ways. Instead of this complexity inhibiting good decisions, insurance customers can use the vast amounts of data from inside and outside sources to make good business decisions that continuously improve the entire company while increasing transactional speed. Ultimately, Omniscience Computational Insurance solutions optimize insurance and financial services companies grow market share, save on costs, boost return on equity, and increase regulatory compliance. Over time many additional Computational Enterprise™ markets will benefit from Omniscience to handle the chaos in their environments. Based in Palo Alto, CA, investors in Omniscience include Guardian Life Insurance Company of America, RGAX, TD Bank, Translink Capital, and others.

All trademarks and registered trademarks are those of their respective companies.


For more press information contact:
Abigail Johnson
Roeder-Johnson Corporation

For more customer information contact:
Omniscience Corporation

Editor Details

  • Company:
    • Businesswire
Last Updated: 15-Jan-2021